Sign in to view content

A Randomized Trial of Intravitreous Anti-VEGF for Prevention of Vision Threatening Complications of Diabetic Retinopathy (Protocol W)

Raj K. Maturi, MD

Video
Published 2021

Related

Phase 2a Study of CU06-1004, an Oral Endothelial Dysfunction Blocker For the Treatment of Diabetic Macular Edema (DME)
Victor Hugo Gonzalez, MD
Annual Meeting Talks
2024
Baseline Characteristics of Patients Who Did or Did Not Maintain 12-Week and 16-Week Aflibercept 8 mg Dosing Intervals in the Phase 2/3 PHOTON Trial
Eric W Schneider, MD
Annual Meeting Talks
2023
Long-Term Outcome of Diabetic Eyes With Vitreous Hemorrhage in an Urban Safety-Net Hospital
Hossein Ameri, MD, PhD, FRCSI, MRCOphth
Annual Meeting Talks
2024

Category: Pharmacology

See more